A special committee of 23andMe's board says it's not “prepared to move forward” with CEO Anne Wojcicki's $0.40-per-share offer to take the company private
A special committee of 23andMe's board said it's not “prepared to move forward” with Chief Executive Officer Anne Wojcicki's offer … X: @carnage4life X: Dare Obasanjo / @carnage4life : 23andMe's board has refused an offer to take the company private by CEO Anne Wojcicki at $0.40 per share as this is the current price and they'd like a premium. This price is -97% from the company's peak stock price of $16 per share. [image]
Context & Ripple Effects
The committee’s refusal came after Wojcicki had already signaled an effort to take 23andMe private amid a steep market-value decline and concerns about its cash runway. The dispute is fundamentally about what value public shareholders should receive in a founder-led transaction.
It also marks an early break in a process that later saw the entire independent board resign while Wojcicki maintained her commitment to a buyout. The subsequent bankruptcy and contested asset sale show how unresolved governance and valuation questions can migrate from public markets into a restructuring process.
First-order effects
- 23andMe’s special committee will not advance Wojcicki’s $0.40-per-share proposal, leaving shareholders without a near-term founder-led exit at that price.
- Wojcicki must improve the economics or structure of any renewed offer, or 23andMe remains public while management pursues its turnaround.
Second-order effects
- The rejection strengthens the committee’s leverage to demand a control premium and a process that can demonstrate fair value to minority shareholders.
- Prolonged uncertainty can constrain strategic options: the company’s declining valuation and cash concerns make it harder to separate operating decisions from negotiations over a take-private.
Third-order effects
- If founder-led privatizations of distressed, data-rich consumer-health companies continue, independent-director process and price discovery will become the central safeguards for public investors.
- 23andMe’s later bankruptcy filing to maximize business value suggests that delayed agreement on a going-private valuation can ultimately shift value determination to creditors, bidders, and court-supervised sales.
The trend: This is one data point in the repricing of data-rich consumer platforms, where fallen public valuations test whether founders can buy assets privately at prices independent boards consider fair.